arrow
C

Carola Berking

friedrich-alexander-universitaet erlangen-nuernberg
H指数:79
被引数:2.6万

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Komplette Lymphknotendissektion versus selektive Lymphknotenexstirpation bei Melanompatienten mit nodaler Makrometastasierung und adjuvanter Systemtherapie

对于黑色素瘤患者伴有结节性巨转移和辅助全身治疗,完全淋巴结清扫术与选择性淋巴结切除的比较

2026-09-060
OAAI
Deep phenotyping of skin tissue remodeling in patients with systemic sclerosis treated with CD19-CAR T cells

系统性硬化症患者经CD19-CAR T细胞治疗后皮肤组织重塑的深度表型分析

2026-05-230
OAAI
Systemic Treatment and Outcome in Erythrodermic Psoriasis: A Retrospective Multicenter Study

红皮病型银屑病的系统性治疗与预后:一项回顾性多中心研究

2026-04-170
OAAI
Vision transformer-based diagnosis of psoriasis and eczema in whole-slide histology

基于视觉变压器的银屑病和湿疹全切片组织学诊断

2026-02-200
OAAI
Role of comorbidities and medication on immunotherapy efficacy in cSCC: A DeCOG multicentre analysis

合并症和药物对cSCC免疫治疗疗效的作用: DeCOG多中心分析

2026-01-290
OAAI
Enhanced overall and progression-free survival in advanced melanoma patients undergoing targeted therapy alongside antithrombotic treatment – Insights from a multicenter study involving 1296 patients from the prospective skin cancer registry ADOReg

接受靶向治疗和抗血栓治疗的晚期黑色素瘤患者的总体和无进展生存期得到提高-来自一项多中心研究的见解,涉及来自前瞻性皮肤癌登记处ADOReg的1296名患者

2025-12-190
OAAI
Auswirkungen auf die Arzneimitteltherapiesicherheit und Adhärenz in der Dermato-Onkologie: Das AMBORA-Therapiebegleitungskonzept für orale Antitumortherapeutika

对药物治疗安全性和依从性的影响以及在皮肤肿瘤学中的体现:口服抗肿瘤药物治疗伴随管理概念——AMBORA方案

2025-10-230
OAAI
Gene expression and molecular pathway analyses differentiate immunotherapy-induced myositis from spontaneous dermatomyositis

基因表达和分子通路分析可将免疫疗法诱导性肌炎与自发性皮肌炎区分开来

2025-08-040
OA
Sex-specific survival in advanced metastatic melanoma – a DeCOG study on 2032 patients of the multicenter prospective skin cancer registry ADOREG

晚期转移性黑色素瘤的性别特异性生存率——一项DeCOG研究,涉及ADOREG多中心前瞻性皮肤癌登记研究的2032例患者。

2025-07-290
OA